The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome

Chemistry Central Journal

Terence Davis²  Michal J Rokicki²  Mark C Bagley¹  David Kipling² 

[1] Department of Chemistry, School of Life Sciences, University of Sussex, Falmer, Brighton, East Sussex, BN1 9QJ, UK

[2] Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK

关键词: Signalling;    Ageing;    Stress;    MAPKAPK2;    MK2;    MAP kinase;    p38;    Senescence;    Werner syndrome;   

Others  :  787974
DOI  :  10.1186/1752-153X-7-18

 received in 2012-12-19, accepted in 2013-01-28,  发布年份 2013

【 摘 要 】

Fibroblasts derived from the progeroid Werner syndrome (WS) show reduced replicative lifespan and a “stressed” morphology, both phenotypes being alleviated by using the p38 MAP kinase inhibitor SB203580. Because p38 is a major hub for the control of stress-signalling pathways we were interested in examining the possible role for downstream kinases in order to refine our understanding of the role of p38 signalling in regulation of WS cell growth. To this end we treated WS and normal fibroblasts with MK2 inhibitors to determine whether MK2 inhibition would affect either the growth or morphology of WS cells. The first inhibitor, 7,8-dihydroxy-2,4-diamino-3-cyanobenzopyranopyridine (inhibitor 2), resulted in inhibition of WS cell growth and had no effect on morphology, effects that occurred below the level needed to inhibit MK2 and thus suggestive of inhibitor toxicity. The second inhibitor, 2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo-[3,2-c]pyridin-4-one (CMPD16), resulted in a significant extension of WS fibroblast replicative capacity compared to normal cells. In addition, CMPD16 reverted the WS cellular morphology to that seen in normal dermal fibroblasts. These data suggest that MK2 activity plays a substantial role in proliferation control in WS cells. CMPD16 was not as effective in cellular lifespan extension as SB203580, however, suggesting that, although MK2 is a downstream kinase involved in cell cycle arrest, other p38 targets may play a role. Alternatively, as CMPD16 is toxic to cell growth at levels just above those that extend lifespan, it is possible that the therapeutic window is too small. However, as CMPD16 does show significant effects in WS fibroblasts, this acts as proof-of-principle for the efforts to design and synthesise improved MK2 inhibitors. As MK2 is involved in inflammatory processes and inflammation plays a major role in WS phenotypes, these data suggest MK2 as a potential therapeutic target for the treatment of Werner syndrome.

【 授权许可】

   
2013 Davis et al.; licensee Chemistry Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kipling D, Davis T, Ostler EL, Faragher RG: What can progeroid syndromes tell us about human aging? Science 2004, 305:1426-1431.
• [2]Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
• [3]Davis T, Baird DM, Haughton MF, Jones CJ, Kipling D: Prevention of accelerated cell aging in Werner syndrome using a p38 mitogen-activated protein kinase inhibitor. J Gerontol A Biol Sci Med Sci 2005, 60:1386-1393.
• [4]Davis T, Kipling D: Werner Syndrome as an example of inflamm-aging: possible therapeutic opportunities for a progeroid syndrome? Rejuvenation Res 2006, 9:402-407.
• [5]Bagley MC, Davis T, Murziani PGS, Widdowson CS, Kipling D: Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome. Phrmaceuticals 2010, 3:1842-1872.
• [6]Kyriakis JM, Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001, 81:807-869.
• [7]Schlapbach A, Huppertz C: Low-molecular-weight MK2 inhibitors: a tough nut to crack! Future Med Chem 2009, 1:1243-1257.
• [8]Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, Yaffe MB: MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 2005, 17:37-48.
• [9]Kotlyarov A, Yannoni Y, Fritz S, Laass K, Telliez JB, Pitman D, Lin LL, Gaestel M: Distinct cellular functions of MK2. Mol Cell Biol 2002, 22:4827-4835.
• [10]Ronkina N, Kotlyarov A, Gaestel M: MK2 and MK3–a pair of isoenzymes? Front Biosci 2008, 13:5511-5521.
• [11]Davis T, Bagley MC, Dix MC, Murziani PG, Rokicki MJ, Widdowson CS, Zayed JM, Bachler MA, Kipling D: Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38α(MAPK) inhibitors in Werner syndrome cells. Bioorg Med Chem Lett 2007, 17:6832-6835.
• [12]Davis T, Haughton MF, Jones CJ, Kipling D: Prevention of accelerated cell ageing in the Werner syndrome. Ann N Y Acad Sci 2006, 1067:243-247.
• [13]Davis T, Dix MC, Rokicki MJ, Brook AJ, Widdowson CS, Kipling D, Bagley MC: Investigating the role of c-Jun N-terminal kinases in the proliferation of Werner syndrome fibroblasts using diaminopyridine inhibitors. Chem Cent J 2011, 5:83. BioMed Central Full Text
• [14]Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Poda GI, Schindler JF, Reitz DB, Mourey RJ: Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem 2007, 50:2647-2654.
• [15]Davis T, Kipling D: Assessing the role of stress signalling via p38 MAP kinase in the premature senescence of Ataxia Telangiectasia and Werner syndrome fibroblasts. Biogerontology 2009, 10:253-266.
• [16]Godl K, Daub H: Proteomic analysis of kinase inhibitor selectivity and function. Cell Cycle 2004, 3:393-395.
• [17]Davis T, Bachler MA, Wyllie FS, Bagley MC, Kipling D: Evaluating the role of p38 MAP kinase in growth of Werner syndrome fibroblasts. Ann N Y Acad Sci 2010, 1197:45-48.